Archives
- 2018-07
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
Our surprising results show that AAD treated
2024-04-27
Our surprising results show that AAD-treated tumors adjacent to adipose tissues and in steatotic liver continue to grow in the presence of a minimal number of microvessels. In non-adipose tumor models, the similar degree of vascular suppression is translated into marked suppression of tumor growth.
-
On the contrary Birrel and colleagues observed divergent
2024-04-27
On the contrary, Birrel and colleagues observed divergent proliferative responses to androgens in different BC cell lines: DHT and mibolerone were found to inhibit the T47-D and ZR-75-1 caspase inhibitor growth, while the proliferation of MCF-7 cells was increased by both the androgens [53]. It is
-
br Conclusions In summary we report a novel
2024-04-27
Conclusions In summary, we report a novel preliminary finding of a potential racial difference in the association of Cd-content and AR expression in prostate cancer that will need to be confirmed in larger studies. Although the association of Cd and AR protein expression is not strong in tumor ti
-
The most common adverse effects were ARIA which occurred
2024-04-27
The most common adverse effects were ARIA, which occurred at higher levels than in any previous anti-Aβ mAb study. ARIA-E was observed at some point during the trial in no participants in the placebo group compared with 1 (3%), 2 (6%), 11 (37%), and 13 (41%) participants receiving 1, 3, 6, and 10 mg
-
Growing evidence indicates that GRKs can exert different eff
2024-04-27
Growing evidence indicates that GRKs can exert different effects within the cell depending on the stimulus, cell type, and localization [97], [121]. In this sense, we were the first to demonstrate a mitochondrial localization for GRK2 [122], later confirmed by other investigators [123], establishing
-
Prochlorperazine There are two ways to transport FFAs
2024-04-27
There are two ways to transport FFAs into cells. First by passive diffusion. Second as the putative long-chain fatty Prochlorperazine transporters are proposed, CD36 the plasma membrane-associated fatty acid-binding protein (FABPpm) and fatty acid transport proteins (FATP) [11], where CD36 is respo
-
Several tertiary prevention studies are currently underway e
2024-04-26
Several tertiary prevention studies are currently underway examining the use of dutasteride for prostate cancer treatment: (1) during expectant management of prostate cancer, (2) after radical prostatectomy in men at high risk for relapse, and (3) in men with metastatic disease. The Reduction by Dut
-
Inhibitors of mPGES are considered as safe alternative to NS
2024-04-26
Inhibitors of mPGES-1 are considered as safe alternative to NSAIDs in the treatment of chronic inflammatory diseases that are characterized by excessive PGE2 production (Bahia et al., 2014; Khurana and Jachak, 2016; Koeberle et al., 2016; Korotkova and Jakobsson, 2014; Norberg et al., 2013; Psarra e
-
br Introduction Nausea and vomiting are among
2024-04-26
Introduction Nausea and vomiting are among the most distressing side effects associated with chemotherapy in cancer patients (Billio et al., 2010). Severe emesis can negatively affect a patient's nutritional state, ability to work and motivation, which can, in turn, interfere with the clinical co
-
Drug resistance development often involves structurally un r
2024-04-26
Drug resistance development often involves structurally un-related drugs and, specifically both conventional and targeted agents. IGROV-1/Pt1 MI-773 are characterized by resistance to cisplatin and reduced sensitivity to inhibitors of EGF-R and MEK, the up-stream activator of ERK1/2, associated wit
-
br Funding br Ethics br Conflict of interest br Acknowledgem
2024-04-26
Funding Ethics Conflict of interest Acknowledgements Introduction Hepatic fibrosis occurs in response to different etiologies of chronic liver injury, which is mainly accompanied by pathological nitric oxide of excessive extracellular matrix (ECM) of the liver, as the common reaction
-
erk inhibitor br Material and methods br Results br Discussi
2024-04-26
Material and methods Results Discussion Although we were not able to detect 12/15-LOX mRNA in the lungs of 12/15-LOX knockout mice substantial amounts of 15-HETE could be detected in BALF. In fact, significant synthesis of 15-HETE in 12/15-LOX mice have been already reported [17]. The redun
-
Tumor suppressor ARF regulates the
2024-04-26
Tumor suppressor ARF regulates the activity of p53 by inhibiting the functions of Mdm2. ARF is induced by hyperproliferative signals emanating from oncogenic Ras, overexpressed c-myc, and from deregulated E2F . ARF prevents p53 degradation and leads to increased p53 function by sequestering Mdm2 to
-
br Results br Discussion Both ATM
2024-04-26
Results Discussion Both ATM and ATR are key regulators of the cellular response to DSBs, yet how exactly they function in concert is not well understood. Recent studies revealed that ATM is required for the resection of DSBs (Jazayeri et al., 2006, Myers and Cortez, 2006), a process necessary
-
br Experimental section br Acknowledgments br Introduction A
2024-04-26
Experimental section Acknowledgments Introduction Adipose is a major endocrine organ which releases a range of bioactive agents [1]. Selected adipose depots have been established as sites of sex steroid metabolism [1]. Subcutaneous and visceral adipose express high levels of aromatase, cap
14922 records 161/995 page Previous Next First page 上5页 161162163164165 下5页 Last page